Molecular diagnostics company Caredx Inc. said it will not be able to provide Allomap tests to Medicare patients if a 74 percent reimbursement cut stands. The blood test is used to determine rejection risk in heart transplant recipients and, according to the company, it is the only alternative to the more invasive and riskier biopsy procedure.